Wednesday, January 25, 2023
Thermo Fisher Scientific announced to partner with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib).
The CDx helps in identify patients with non-small cell lung cancer (NSCLC), eligible for treatment with Tagrisso by identifying tumours that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations.
The collaboration will leverage the Oncomine Dx Express Test* on the Genexus Dx System*, a fully-integrated next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster. NGS-based CDx testing offers the ability to detect multiple biomarkers from a single test, helping to match patients with an appropriate targeted therapy more quickly.
Tagrisso is currently approved in numerous countries and regions around the world for the following indications: the treatment of patients with locally advanced or metastatic EGFR T790M mutation positive NSCLC; the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; and, the adjuvant treatment after tumour resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
